

Contents

1.	From Primary to Secondary Prevention	16
1.1.	Definition.....	16
1.2.	Risk factors for atherosclerosis	17
1.3.	Aims of secondary prevention.....	17
1.4.	Primary versus secondary prevention.....	18
1.5.	Blood pressure/HbA _{1c} goals	19
1.6.	HbA _{1c} target in diabetics.....	21
1.7.	Lipids.....	21
1.8.	Non-pharmacological therapeutic measures.....	22
1.9.	Summary	23
1.10.	References.....	23
2.	Manifestations and Prognosis of CAD	25
2.1.	Manifestations of atherosclerosis	25
2.2.	Manifestations of CAD	25
2.3.	Prognosis in CAD	26
2.4.	Prognosis and gender.....	27
2.5.	Prognosis in renal insufficiency.....	28
2.6.	Prognosis and diabetes	28
2.7.	Prognosis and type of medical care.....	29
2.8.	Prognosis in STEMI versus NSTEMI.....	29
2.9.	Decrease in CAD mortality?	29
2.10.	Summary	30
2.11.	References.....	31
3.	From the Endothelial Defect to Myocardial Infarction	32
3.1.	The importance of the endothelium	32
3.2.	The acetylcholine test as a method to demonstrate endothelial dysfunction	33
3.3.	Clinical impact of endothelial dysfunction during stress	33
3.4.	Endothelial dysfunction as a prognostic indicator.....	34
3.5.	Endothelial progenitor cells	34
3.6.	Atherosclerosis in the coronary region.....	35
3.7.	From atherothrombosis to the acute syndrome.....	37
3.8.	Remodelling of the left ventricle after myocardial infarction.....	38
3.9.	Summary	38
3.10.	References.....	39
4.	Pathophysiology of CAD and Strategies for Secondary Prevention	41
4.1.	Coronary insufficiency	41
4.2.	Determinants of the myocardial O ₂ requirement	42
4.3.	Strategies for secondary prevention	42

4.4.	Therapeutic priorities depending on the form of presentation of CHD	43
4.5.	Summary	44
4.6.	References.....	44
5.	Nitrates and Other Antianginal Agents	46
5.1.	Mechanism of action of nitrates	46
5.2.	Nitrate drugs	46
5.3.	Do nitrates prolong survival in CAD?.....	47
5.4.	Nitrates in secondary prevention	48
5.5.	Molsidomine	48
5.6.	Trapidil	48
5.7.	Potassium channel openers (nicorandil)	49
5.8.	Ranolazine.....	49
5.9.	Summary	50
5.10.	References.....	51
6.	Beta-Blockers	53
6.1.	Mechanism of action of beta-blockers	53
6.2.	Classification of beta-blockers	53
6.3.	Differences between beta-blockers	53
6.4.	Treatment aims on beta-blockers	54
6.5.	Beta-blockers in post-infarct patients	54
6.6.	Who benefits most?.....	55
6.7.	Do all beta-blockers have a secondary prevention effect?	57
6.8.	Can beta-blockers be used for secondary prevention in CAD without infarction?	57
6.9.	Beta-blockers in heart failure	57
6.10.	Third-generation beta-blockers	58
6.11.	Beta-blockers in LV dysfunction after infarction, the CAPRICORN study	58
6.12.	2007 AHA/ACC Guidelines	59
6.13.	The 2008 ESC guidelines	59
6.14.	Summary	59
6.15.	References.....	60
7.	Calcium Antagonists	62
7.1.	Mechanism of action of calcium antagonists	62
7.2.	Differences between the calcium antagonists	62
7.3.	Calcium antagonists in stable angina	62
7.4.	Dihydropyridines in postinfarct patients	63
7.5.	Diltiazem in postinfarct patients	63
7.6.	Verapamil in postinfarct patients	64
7.7.	Hypertensive versus normotensive postinfarct patients	65
7.8.	Third-generation calcium antagonists in CAD	65
7.9.	Summary	67
7.10.	References.....	68

8.	ACE Inhibitors	70
8.1.	Mechanism of action	70
8.2.	Pathophysiological basis of ACE inhibitor treatment	70
8.3.	ACE inhibitors and aspirin	72
8.4.	Postinfarction studies with ACE inhibitors	73
8.5.	ACE inhibitors and risk of atrial fibrillation	76
8.6.	The HOPE study	76
8.7.	ACE inhibitors and rate of infarction	78
8.8.	ACE inhibitors in association with and after PTCA – the QUIET study	78
8.9.	ACE inhibitors in association with and after CABG – the QUO VADIS study	79
8.10.	ACE inhibitors in CAD patients with a lower risk	79
8.11.	2006/2007 ACC/AHA guidelines	81
8.12.	Summary	82
8.13.	References	82
9.	AT₁ Receptor Blockers	85
9.1.	The mechanism of action	85
9.2.	AT ₁ receptor blockers and pleiotropic effects	85
9.3.	Clinical studies in CAD	86
9.4.	Combination of ACE inhibitor plus AT ₁ receptor blocker	89
9.5.	2006/2007 ACC/AHA- and 2008 ESC-guidelines	89
9.6.	Summary	89
9.7.	References	90
10.	Statins (HMG-CoA Reductase Inhibitors)	91
10.1.	Situation before the statin era	91
10.2.	Mechanism of action of the statins	91
10.3.	A comparison of statins	91
10.4.	Statins and dose-effect relationship	93
10.5.	Statins in secondary prevention – the evidence from studies	93
10.6.	The time for using an HMG-CoA reductase inhibitor during and after acute coronary syndrome	98
10.7.	Statins and number of revascularisations	98
10.8.	ACE inhibitors after CABG and PTCA	99
10.9.	HMG-CoA reductase inhibitors in PTCA	100
10.10.	Who benefits from LDL lowering? Younger or older patients?	101
10.11.	Additional vascular effects of HMG-CoA reductase inhibitors	102
10.12.	LDL lowering and cardiac risk – the greater the LDL reduction, the better	107
10.13.	LDL treatment targets today	110
10.14.	Statins in high-risk patients	112
10.15.	Fibrates in secondary prevention	113
10.16.	2006/2007 ACC/AHA guidelines	114
10.17.	Summary	115
10.18.	References	115

11.	Antiplatelet Agents	119
11.1.	Antiplatelet agents – an overview	119
11.2.	Mechanism of action of antiplatelet agents	119
11.3.	Molecular target of the thienopyridines	120
11.4.	Prasugrel versus clopidogrel	120
11.5.	Clopidogrel and interaction with PPIs	121
11.6.	Rebound phenomena and resistance	122
11.7.	Ticagrelor and cangrelor	123
11.8.	Glycoprotein IIb/IIIa Receptor Inhibitors	123
11.9.	Aspirin (acetylsalicylic acid, ASS)	123
11.10.	Aspirin plus low-dose coumarins	125
11.11.	Clopidogrel	126
11.12.	Clopidogrel plus aspirin	127
11.13.	Oral glycoprotein IIb/IIIa receptor inhibitors	131
11.14.	Current guidelines	131
11.15.	Summary	133
11.16.	References	133
12.	Anticoagulants	137
12.1.	The Sixty Plus study in the elderly	137
12.2.	The WARIS-1 study	137
12.3.	The ASPECT-1 study	137
12.4.	The ASPECT-2 study	138
12.5.	The WARIS-2 study	138
12.6.	The APRICOT-2 study	138
12.7.	Indications for coumarins today	138
12.8.	Antithrombotic treatment in atrial fibrillation	139
12.9.	Dabigatran in atrial fibrillation – the RE-LY study	141
12.10.	Summary	142
12.11.	References	142
13.	Antihypertensive Agents	144
13.1.	Hypertension and risk in CAD	144
13.2.	The HOPE study	144
13.3.	Subgroup analysis of the CAD patients in the HOT study	144
13.4.	Isolated systolic hypertension (ISH)	145
13.5.	The RENAAL study and IDNT study	145
13.6.	The INVEST study	145
13.7.	The VALUE study	146
13.8.	Blood pressure versus change in plaque size	146
13.9.	Which combination therapy – the ACCOMPLISH study	147
13.10.	Target blood pressure values in CAD	148
13.11.	Calcium antagonists plus ACE inhibitors in chronic stable CAD	148
13.12.	Summary	149
13.13.	References	149

14.	Omega-3 Fatty Acids	150
14.1.	The GISSI Prevention study	150
14.2.	Recommendations of the ESC, AHA, NICE	151
14.3.	The OMEGA study	152
14.4.	Summary	152
14.5.	References	152
15.	Ivabradine, the I_r Channel Blocker	154
15.1.	The BEAUTYUL study	154
15.2.	Summary	155
15.3.	References	155
16.	Unstable Angina Pectoris/Non-Q-Wave Infarction (NSTEMI)	157
16.1.	Definition	157
16.2.	The prognosis in unstable angina/non-Q-wave infarction	157
16.3.	Aims of treatment	158
16.4.	Nitrates in unstable angina/non-Q-wave infarction	158
16.5.	Beta-blockers	158
16.6.	Calcium antagonists	159
16.7.	Aspirin	159
16.8.	Heparin in unstable angina/NSTEMI	159
16.9.	Pentasaaccharides	161
16.10.	Bivalirudin	161
16.11.	GP IIb/IIIa receptor inhibitors in unstable angina	161
16.12.	Clopidogrel plus aspirin in unstable angina/non-Q-wave infarction	163
16.13.	Prasugrel versus clopidogrel	167
16.14.	Statins in acute coronary syndrome	172
16.15.	Invasive versus non-invasive approach in unstable angina/NSTEMI	174
16.16.	The importance of GP IIb/IIIa receptor inhibitors in PCI	177
16.17.	The combination of GP IIb/IIIa inhibitors, aspirin, heparin, clopidogrel	178
16.18.	Improvement in prognosis in NSTEMI-ACS	178
16.19.	Approach in unstable angina/NSTEMI (2007/2009 ESC and ACC/AHA guidelines)	178
16.20.	Algorithm in the case of ACS – 2007 ESC guidelines	182
16.21.	The GRACE risk score	182
16.22.	Ticagrelor in ACS	182
16.23.	Summary	184
16.24.	References	186
17.	The Treatment of Acute Myocardial Infarction (STEMI)	190
17.1.	The effect of thrombolysis	190
17.2.	Aspirin	193
17.3.	Clopidogrel	195
17.4.	Prasugrel vs clopidogrel in STEMI – the TRITON-TIMI 38 study	196
17.5.	Anticoagulation	197
17.6.	Nitrates	198

17.7.	Beta-blockers	200
17.8.	ACE inhibitors/AT ₁ receptor blockers	201
17.9.	AT ₁ receptor blockers	203
17.10.	Calcium antagonists	203
17.11.	Antiarrhythmics (lidocaine prophylaxis)	203
17.12.	PTCA in acute infarction (STEMI).....	203
17.13.	Lysis versus transport to a PCI centre	204
17.14.	PTCA versus PTCA plus stent	205
17.15.	PTCA plus stent plus GP IIb/IIIa inhibitor	205
17.16.	Rescue PCI/facilitated PCI	206
17.17.	National differences in the hospitalisation time	207
17.18.	The prognosis in STEMI	207
17.19.	The new classification of infarction	207
17.20.	2009 and 2008 guidelines of the ACC/AHA and ESC	207
17.21.	DES versus BMS in STEMI – the HORIZONS-AMI study	209
17.22.	Summary.....	209
17.23.	References	211
18.	Elective Revascularisation Procedures in CAD	216
18.1.	Bypass surgery	216
18.2.	PTCA	218
18.3.	Stents	219
18.4.	PTCA versus CABG	222
18.5.	PTCA versus atherectomy	223
18.6.	Transmyocardial laser revascularisation	224
18.7.	Beta-blockers before CABG	225
18.8.	Coronary angiography versus fractional flow reserve as a parameter for indicating PCI – the FAME study.....	225
18.9.	Surgical ventricle reconstruction – the STICH study	225
18.10.	Adherence to guidelines for PCI and CABG	226
18.11.	Measures in refractory angina.....	226
18.12.	CABG versus minimally invasive surgery	227
18.13.	Summary.....	227
18.14.	References	228
19.	Conservative Therapy Versus Interventional/Surgical Therapy	232
19.1.	Current secondary prevention and targets.....	232
19.2.	Additive effects with four secondary prevention agents?.....	232
19.3.	Individual conservative measures in chronic stable CAD versus PCI	235
19.4.	Optimised secondary prevention versus PCI with stent	236
19.5.	Is late reperfusion worthwhile? The open artery hypothesis	238
19.6.	Optimised secondary prevention vs PCI in diabetes – the BARI 2D study	238
19.7.	Meta-analyses on optimised secondary prevention vs PCI	239

19.8.	No successes with low risk	240
19.9.	Conservative versus interventional/surgical therapy	241
19.10.	The problem and a suggested solution	242
19.11.	COURAGE and Wall Street – a controversial subject	242
19.12.	Summary: prioritising before rationing	244
19.13.	Summary	244
19.14.	References	245
20.	Postinfarction Failure	248
20.1.	Pathophysiological background	248
20.2.	Spironolactone in NYHA class III and IV	248
20.3.	Eplerenone after acute myocardial infarction with LV dysfunction	248
20.4.	Guidelines on aldosterone antagonists after myocardial infarction	249
20.5.	2006/2007 ACC/AHA guidelines and 2008 ESC guidelines	249
20.6.	Summary	250
20.7.	References	250
21.	Antiarrhythmic Drugs	251
21.1.	Pathophysiological background	251
21.2.	The pro-arrhythmogenic effect in relation to the ejection fraction	251
21.3.	Clinical studies in ventricular extrasystoles	251
21.4.	Amiodarone in heart failure	252
21.5.	Amiodarone in post-infarct patients	253
21.6.	Antiarrhythmics in atrial fibrillation	254
21.7.	Summary	259
21.8.	References	260
22.	ICD, CRT, Cardiac Pacemakers	262
22.1.	The implantable defibrillator (ICD)	262
22.2.	Resynchronisation therapy (CRT)	268
22.3.	Programmed stimulation for risk identification	272
22.4.	Cardiac pacemaker therapy	272
22.5.	Summary	273
22.6.	References	274
23.	Lifestyle, Body Weight, Smoking, Alcohol, Physical Activity and Rehabilitation	277
23.1.	Diet	277
23.2.	Normalisation of body weight	279
23.3.	Smoking	281
23.4.	Alcohol	284
23.5.	Physical activity and rehabilitation	287
23.6.	When should lifestyle changes begin?	289
23.7.	Summary	289
23.8.	References	290

24.	HDL, Triglycerides, Lp(a), the Forgotten Lipid Fractions	294
24.1.	Hyperlipoproteinaemias, an overview	294
24.2.	Associations between lipids.....	294
24.3.	Lipid-lowering drugs	296
24.4.	HDL	296
24.5.	Triglycerides.....	301
24.6.	What do the guidelines say?	305
24.7.	Lipoprotein (a).....	306
24.8.	All lipid fractions are important	307
24.9.	Summary.....	307
24.10.	Literatur.....	309
25.	Abbreviations	312
	Index	314